Loading...

IRD OPUS GENETICS INC Investments/Divestments 8-K Filing

PS G

RD

OPUS GENETICS INC

(IRD)

2023 8-K

Show Summary

Show Summary

Financial Statements

Agreement Termination

Financial Results

Financial Results

Bylaw Amendments

Patent Challenge

Executive Changes

Annual Meeting Notice

Equity Offering

Acquisition Completed

Financial Results

Merger Completion

Q2 Financial Results

Amendment and Restated Bylaws

Regulation FD Disclosure

Earnings Reports

Consulting Agreement with D...

Investor Meetings

Financial Results Announcement

Appointment of CFO

Appointment of Chief Busine...

Appointment of Chief Operat...

Financial Results Announcement

Corporate Presentation and ...

Appointment of CEO

FDA Approval and Milestone ...

Stock Purchase Agreement

Regulation FD Disclosure

Departure of CEO

Annual Meeting Results

Bylaws Amendment

Financial Results Announcement

Termination of CEO and Appo...

Financial Results Announcement

Earnings Reports

External Links:

Ocuphire Pharma, Inc. posted an updated corporate presentation and announced the successful outcome of an End-of-Phase 2 meeting with the FDA for the advancement of oral APX3330 for the treatment of diabetic retinopathy into Phase 3 studies.

AI Assistant

OPUS GENETICS INC

2023

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.